MedTrace Logo

Study of Palliative Radiotherapy for Symptomatic Hepatocellular Carcinoma and Liver Metastases

NCT02511522 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2024-10-23

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to see whether one dose of palliative radiation therapy directed to the liver in combination with standard BSC might help to reduce liver pain/discomfort due to cancer when compared to getting standard BSC alone.

Conditions

Interventions

OTHER

Best Supportive Care

Including analgesics, palliative care and/or pain specialist assessment as needed

RADIATION

Palliative Radiation Therapy

8 Gy in 1 fraction in whole liver or near whole liver. Including anti-emetic pre-medications

Sponsors & Collaborators

  • Canadian Cancer Trials Group

    lead NETWORK

Principal Investigators

  • Laura Ann Dawson · Univ. Health Network-Princess Margaret Hospital

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-11
Primary Completion
2022-10-26
Completion
2024-10-02

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02511522 on ClinicalTrials.gov